**Creatine Kinase (Two Part Liquid) Reagent Set**

**Intended Use**
For the quantitative determination of creatine kinase activity in serum.

**Summary and Principle**
Serum creatinine kinase (CK) levels have proven valuable in the assessment of cardiac and skeletal muscle diseases, including myocardial infarction and muscular dystrophy. Determination of creatine kinase and lactate dehydrogenase isoenzymes provides a definitive diagnosis of acute myocardial infarction.

The kinetic procedure presented is a modification of Szasz's technique, which optimizes the reaction by reactivation of CK activity with N-acetyl-L-cysteine (NAC).

CK specifically catalyzes the transphosphorylation of ADP to ATP. Through a series of coupled enzymatic reactions, NADPH is produced at a rate directly proportional to the CK activity. The method determines the NADPH absorbance increase per min at 340 nm.

**Reagents**

CK R1 (buffer) contains: Imidazole buffer (pH 6.7) 100.0 mmol/L; NADP 2.0 mmol/L; HK (Baker's yeast) 2.5 KU/L; Glucose 20.0 mmol/L; Magnesium Acetate 10.0 mmol/L; EDTA 2.0 mmol/L and N-acetylcysteine (NAC) 20.0 mmol/L.

CK R2 (enzyme reagent) contains: Imidazole buffer (pH 6.7) 100.0 mmol/L; ADP 2.0 mmol/L; AMP 5.0 mmol/L; Diadenosine pentaphosphate 10.0 mmol/L; Creatine phosphate 30.0 mmol/L; G6PDH (Baker's yeast) 1.5 KU/L and EDTA 2.0 mmol/L.

**Reagent Preparation**
Reagents are supplied as ready to use liquids. To prepare working reagent, mix 4 parts of R1 (buffer) with 1 part R2 (enzyme).

**Reagent Storage**
1. Reagents should appear clear and colorless. Discard if either appears cloudy or contains particulate matter.
2. Store R1 and R2 at 2-8°C, protected from light. If stored as directed the reagents are stable until the expiration date.
3. Working reagent is stable for 3 weeks at 2-8°C or 2 days at room temperature (15-30°C).

**Precautions**
1. This reagent is for in vitro diagnostic use only.
2. Normal precautions in handling laboratory reagents should be followed.
3. The reagents contain sodium azide which may be toxic if ingested. Sodium azide may also react with lead and copper plumbing to form highly explosive metal azides. Refer to Material Safety Data Sheet for any updated risk, hazard or safety information.

**Specimen Collection and Handling**
1. Clear unhemolyzed serum is the specimen of choice. No special additives or preservatives are required.
2. Whenever possible, specimens should be separated and analyzed on the day of collections and stored in capped tubes.

**Interferences**
1. Intramuscular injections and strenuous physical exercise may elevate serum CK.
2. Chloride and sulfate inhibit CK activity.
3. Bilirubin levels up to 40 mg/dl and triglyceride levels up to 2000 mg/dl show no interference in this test.
4. Young, et al. have reviewed drug effects on serum CK levels.

**Materials Provided**
CK R1 and R2 Reagent.

**Materials Required but not Provided**
1. Test tubes/rack
2. Pipetting devices
3. Spectrophotometer with the ability to read at 340nm and 1 cm light path.
4. Timer
5. Heating Block (37°C)

**Procedure (Automated)**
Refer to specific instrument application instructions.

**Procedure (Manual)**
1. Prepare working reagent according to instructions.
2. Pipette 1.0ml of working reagent into appropriate tubes and pre-warm at 37°C for 4 minutes.
4. Add 0.05 ml (50 ul) sample to its respective test tube and mix gently.
5. After two minutes, read and record the absorbance. Return tube to 37°C.
6. Repeat readings every minute for the next two minutes. The rate should be constant.
7. Calculate the average absorbance difference per minute ΔAbs./min.
8. Multiply the ΔAbs./min by the factor 3376 for results in U/L.

NOTE: If cuvette is not temperature controlled, incubate samples at 37°C between readings.

**Calibration**
CK activity is based on the "micromolar extinction coefficient" of NADP at 340 nm (see "Calculations" section). The instrument manufacturer's calibration guidelines should be followed to calibrate your analyzer. Assaying the CK contents of a control serum with known CK values can be used to assure instrument calibration has been performed correctly.

**Calculations**
Values are derived based on the "absorptivity micromolar extinction coefficient" of NADP at 340 nm (0.00622). A unit per liter (U/L) of CK activity is that amount of enzyme which oxidizes one μmol/L of NADP per minute.

\[
U/L = \Delta \text{Abs./min} \times 1.05 \\
0.00622 \\
0.05
\]
Creatine Kinase  
(Two Part Liquid)  
Reagent Set

\[
\text{U/L} = \frac{\Delta A/\text{Min} \times \text{Total Volume}}{0.00622} \quad \text{Sample Volume}
\]

\[
\text{U/L} = \Delta A/\text{Min} \times 3376
\]

Limitations
If the \(\Delta \text{Abs./min}\) is greater than 0.345, dilute 1 part sample with 9 parts saline and re-assay. Multiply results by 10. CK values for neonatal patients have not been established with this procedure.

Quality Control
The validity of the reaction should be monitored by use of control sera with known normal and abnormal creatine kinase values. These conditions should be run at least with every working shift in which creatine kinase assays are performed. It is recommended that each laboratory establish its own frequency of control determination.

Expected Values
Normal range:  
Males: 38-174 U/L (37°C)  
Females: 26-140 U/L (37°C)

The range should serve only as a guideline. It is recommended that each laboratory establish its own range of expected values, since differences exist between instruments, laboratories and local populations.

Performance Characteristics
Comparison: A group of 77 sera ranging in CK activity from 3 - 700 U/L was assayed by the described CK method and by a similar commercially available CK reagent. Comparison of the results yielded a correlation coefficient of 0.999 and the regression equation was \(y = 1.027x - 0.65\). (Comparison studies were performed according to NCCLS Tentative Guideline, EP9-T).

Precision: Within-run precision was established by 20 assays on three different levels of commercial controls. Total Precision values were obtained by assaying 3 commercial controls for 5 consecutive days.

<table>
<thead>
<tr>
<th>Within-Run</th>
<th>Serum 1</th>
<th>Serum 2</th>
<th>Serum 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean CK (U/L)</td>
<td>199</td>
<td>220</td>
<td>508</td>
</tr>
<tr>
<td>Std. Deviation (U/L)</td>
<td>3.2</td>
<td>1.5</td>
<td>3.7</td>
</tr>
<tr>
<td>C.V. (%)</td>
<td>2.0</td>
<td>0.7</td>
<td>0.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Precision</th>
<th>Serum 1</th>
<th>Serum 2</th>
<th>Serum 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean CK (U/L)</td>
<td>50</td>
<td>157</td>
<td>228</td>
</tr>
<tr>
<td>Std. Deviation (U/L)</td>
<td>1.1</td>
<td>1.6</td>
<td>2.3</td>
</tr>
<tr>
<td>C.V. (%)</td>
<td>2.1</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Precision studies were performed according to NCCLS Tentative Guideline, EP5-T.

Linearity: Linear from 1 to 1200 U/L at 37°C.\(^8\) Performed according to NCCLS Guideline EP6-P.

Sensitivity: Based on an instrument resolution of \(A = 0.001\), the method presented shows a sensitivity of 1.0 U/L.

References
9. Manufacturer's Laboratory Data

Manufactured for Pointe Scientific, Inc.  
5449 Research Drive, Canton, MI 48188

European Authorized Representative: 
Obelis s.a.  
Boulevard Général Wahis 53  
1030 Brussels, BELGIUM  
Tel: (32)2.732.59.54  Fax:(32)2.732.60.03  email: mail@obelis.net

Rev. 10/11 P803-C7522-01